205 related articles for article (PubMed ID: 35029054)
1. Primary skeletal muscle cells from chronic kidney disease patients retain hallmarks of cachexia in vitro.
Baker LA; O'Sullivan TF; Robinson KA; Graham-Brown MPM; Major RW; Ashford RU; Smith AC; Philp A; Watson EL
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1238-1249. PubMed ID: 35029054
[TBL] [Abstract][Full Text] [Related]
2. Long-noncoding RNA Atrolnc-1 promotes muscle wasting in mice with chronic kidney disease.
Sun L; Si M; Liu X; Choi JM; Wang Y; Thomas SS; Peng H; Hu Z
J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):962-974. PubMed ID: 30043444
[TBL] [Abstract][Full Text] [Related]
3. TLR13 contributes to skeletal muscle atrophy by increasing insulin resistance in chronic kidney disease.
Gu L; Wang Z; Zhang Y; Zhu N; Li J; Yang M; Wang L; Rong S
Cell Prolif; 2022 Mar; 55(3):e13181. PubMed ID: 35088922
[TBL] [Abstract][Full Text] [Related]
4. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
Solagna F; Tezze C; Lindenmeyer MT; Lu S; Wu G; Liu S; Zhao Y; Mitchell R; Meyer C; Omairi S; Kilic T; Paolini A; Ritvos O; Pasternack A; Matsakas A; Kylies D; Wiesch JSZ; Turner JE; Wanner N; Nair V; Eichinger F; Menon R; Martin IV; Klinkhammer BM; Hoxha E; Cohen CD; Tharaux PL; Boor P; Ostendorf T; Kretzler M; Sandri M; Kretz O; Puelles VG; Patel K; Huber TB
J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 34060483
[TBL] [Abstract][Full Text] [Related]
5. Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease.
Yu R; Chen JA; Xu J; Cao J; Wang Y; Thomas SS; Hu Z
J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):327-341. PubMed ID: 27897418
[TBL] [Abstract][Full Text] [Related]
6. Signal regulatory protein alpha initiates cachexia through muscle to adipose tissue crosstalk.
Wu J; Dong J; Verzola D; Hruska K; Garibotto G; Hu Z; Mitch WE; Thomas SS
J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1210-1227. PubMed ID: 31507080
[TBL] [Abstract][Full Text] [Related]
7. The role of IL-1 in adipose browning and muscle wasting in CKD-associated cachexia.
Cheung WW; Zheng R; Hao S; Wang Z; Gonzalez A; Zhou P; Hoffman HM; Mak RH
Sci Rep; 2021 Jul; 11(1):15141. PubMed ID: 34302016
[TBL] [Abstract][Full Text] [Related]
8. Skeletal myopathy in CKD: a comparison of adenine-induced nephropathy and 5/6 nephrectomy models in mice.
Kim K; Anderson EM; Thome T; Lu G; Salyers ZR; Cort TA; O'Malley KA; Scali ST; Ryan TE
Am J Physiol Renal Physiol; 2021 Jul; 321(1):F106-F119. PubMed ID: 34121452
[TBL] [Abstract][Full Text] [Related]
9. Growth Hormone Improves Adipose Tissue Browning and Muscle Wasting in Mice with Chronic Kidney Disease-Associated Cachexia.
Mak RH; Gunta S; Oliveira EA; Cheung WW
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499637
[TBL] [Abstract][Full Text] [Related]
10. Signal regulatory protein-α interacts with the insulin receptor contributing to muscle wasting in chronic kidney disease.
Thomas SS; Dong Y; Zhang L; Mitch WE
Kidney Int; 2013 Aug; 84(2):308-16. PubMed ID: 23515050
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.
Yoshida T; Tabony AM; Galvez S; Mitch WE; Higashi Y; Sukhanov S; Delafontaine P
Int J Biochem Cell Biol; 2013 Oct; 45(10):2322-32. PubMed ID: 23769949
[TBL] [Abstract][Full Text] [Related]
12. Calycosin inhibited autophagy and oxidative stress in chronic kidney disease skeletal muscle atrophy by regulating AMPK/SKP2/CARM1 signalling pathway.
Hu R; Wang MQ; Liu LY; You HY; Wu XH; Liu YY; Wang YJ; Lu L; Xiao W; Wei LB
J Cell Mol Med; 2020 Oct; 24(19):11084-11099. PubMed ID: 32910538
[TBL] [Abstract][Full Text] [Related]
13. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy.
Zhang L; Wang XH; Wang H; Du J; Mitch WE
J Am Soc Nephrol; 2010 Mar; 21(3):419-27. PubMed ID: 20056750
[TBL] [Abstract][Full Text] [Related]
14. Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia.
Lee JH; Kim SW; Kim JH; Kim HJ; Um J; Jung DW; Williams DR
Cells; 2021 Apr; 10(5):. PubMed ID: 33925786
[TBL] [Abstract][Full Text] [Related]
15. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia.
AlSudais H; Rajgara R; Saleh A; Wiper-Bergeron N
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):743-757. PubMed ID: 35014202
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
17. Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease.
Zhang YY; Yang M; Bao JF; Gu LJ; Yu HL; Yuan WJ
BMC Nephrol; 2018 Feb; 19(1):45. PubMed ID: 29486729
[TBL] [Abstract][Full Text] [Related]
18. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
19. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486.
Xu J; Li R; Workeneh B; Dong Y; Wang X; Hu Z
Kidney Int; 2012 Aug; 82(4):401-11. PubMed ID: 22475820
[TBL] [Abstract][Full Text] [Related]
20. Muscle Atrophy in CKD: A Historical Perspective of Advancements in Its Understanding.
Price SR; Mitch WE; Garibotto G
J Ren Nutr; 2023 Nov; 33(6S):S88-S92. PubMed ID: 36183901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
